Both genetic deficiency and pharmacological inhibition of DHCR7 (the enzyme that converts 7-DHC to cholesterol) lead to 7-DHC accumulation, conferring robust resistance to ferroptosis in cancer cells and promoting more aggressive tumor phenotypes in vivo. Here, DHCR7 is linked to cancer.